MK-677 (Ibutamoren): Research Overview

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

MK-677, also referred to as Ibutamoren, Oratrope, or Crescendo, is a selective agonist of the ghrelin receptor, functioning as a growth hormone secretagogue. Experimental evidence indicates that MK-677 elevates growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentrations without concurrently raising cortisol levels. This pharmacological profile suggests potential therapeutic applications in growth hormone deficiency, musculoskeletal disorders, age-related decline, sleep disturbances, and appetite stimulation.

Chemical Characteristics and Bioavailability

MK-677 is a synthetic non-peptidic molecule derived from benzolactam structures modeled after GHRP-6. Unlike selective androgen receptor modulators (SARMs) or peptide-based GH secretagogues, MK-677 is classified as a small-molecule metabolic modulator.

A clinically relevant advantage of MK-677 is its oral bioavailability. Unlike most GH secretagogues that require subcutaneous or intramuscular delivery, MK-677 is effective via oral administration. Furthermore, it demonstrates an extended elimination half-life of up to 24 hours in humans.

Cortisol-Sparing Effects

Cortisol plays a critical role in glucose metabolism, immune regulation, and fluid balance. However, excessive cortisol secretion can result in muscle catabolism, fat accumulation, bone demineralization, and immune suppression. Some growth hormone secretagogues inadvertently stimulate cortisol release, limiting their therapeutic potential. Clinical studies suggest that MK-677 does not elevate cortisol concentrations.

Potential Role in Age-Related Decline

Physiological GH secretion declines progressively after early adulthood, with marked reductions evident by the seventh decade of life. This decline, termed somatopause, contributes to sarcopenia, osteoporosis, adiposity, reduced vitality, and impaired immune function. MK-677 has been studied for its ability to restore GH levels to more youthful ranges.

Influence on Sleep Regulation

Age-related decreases in GH correlate with diminished slow-wave and rapid eye movement (REM) sleep. Disturbances in these sleep stages are linked to cognitive decline, weakened immunity, and impaired recovery processes. MK-677 has been shown to improve sleep architecture by increasing both stage 4 (slow-wave) and REM sleep.

Cardiovascular and Endothelial Health

Endothelial progenitor cells (EPCs), vital for vascular repair and angiogenesis, decline with age, contributing to atherosclerosis and heightened cardiovascular risk. Preclinical research indicates that MK-677 enhances EPC survival and function, potentially mitigating vascular aging.

Additionally, GH stimulation increases nitric oxide synthase activity, leading to elevated nitric oxide (NO) production. Higher NO levels are associated with improved vascular function, reduced blood pressure, enhanced endothelial health, and protection against cardiovascular and neurodegenerative diseases.

Summary and Research Directions

Its oral availability, extended half-life, and lack of cortisol or androgen suppression make it a promising candidate for future therapeutic applications.

Ongoing studies continue to evaluate its role in conditions such as adult frailty, Alzheimer’s disease, and cardiovascular decline. The most consistent finding remains its ability to increase GH and IGF-1 secretion.

REFERENCES

1. Devin, J. K., Vaughan, D. E., Blevins, L. S., Jr, Chen, Q., Covington, J., Verity, D. K., & Young, P. P. (2008). Low-dose growth hormone administration mobilizes endothelial progenitor cells in healthy adults. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 18(3), 253–263. https://doi.org/10.1016/j.ghir.2007.11.001
2. Thum, T., Hoeber, S., Froese, S., Klink, I., Stichtenoth, D. O., Galuppo, P., Jakob, M., Tsikas, D., Anker, S. D., Poole-Wilson, P. A., Borlak, J., Ertl, G., & Bauersachs, J. (2007). Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circulation research, 100(3), 434–443. https://doi.org/10.1161/01.RES.0000257912.78915.af
3. Copinschi G, et al. Sleep and endocrine changes after administration of growth hormone secretagogue MK-677 in healthy young and older adults. Sleep. 1997;20(12):1027–1034.
4. Schüssler P, et al. Effects of ghrelin and GH secretagogues on sleep regulation in humans. Neuroendocrinology. 2005;81(4):273–280.
5. Thum T, et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth hormone therapy. Eur Heart J. 2007;28(9):1232–1238.
6. Napoli R, et al. Growth hormone replacement therapy improves vascular function in growth hormone-deficient adults. J Clin Endocrinol Metab. 2002;87(3):1083–1089.